Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

RETRACTED: Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation

(2013) Peng Yi et al.   CELL

Role of KATP Channels in Glucose-Regulated Glucagon Secretion and Impaired Counterregulation in Type 2 Diabetes

(2013) Quan Zhang et al.   Cell Metabolism

Tolbutamide Controls Glucagon Release From Mouse Islets Differently Than Glucose: Involvement of KATP Channels From Both  -Cells and  -Cells

(2013) R. Cheng-Xue et al.   DIABETES

Glucose regulation of glucagon secretion

(2013) Erik Gylfe et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

(2013) Steven E Kahn et al.   LANCET

The SLC2 (GLUT) family of membrane transporters

(2013) Mike Mueckler et al.   MOLECULAR ASPECTS OF MEDICINE

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats

(2012) Takumi Nagata et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Improved glycemic control in mice lacking Sglt1 and Sglt2

(2012) David R. Powell et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Glucose Transport by Acinar Cells in Rat Parotid Glands

(2012) Cedric Jurysta et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

(2012) G. Luippold et al.   DIABETES OBESITY & METABOLISM

Adaptive changes of human islets to an obesogenic environment in the mouse

(2012) S. Gargani et al.   DIABETOLOGIA

Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice

(2012) Atsuo Tahara et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models

(2012) Yin Liang et al.   PLoS One

Glucagon regulates its own synthesis by autocrine signaling

(2012) B. Leibiger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function

(2011) Michael J. Jurczak et al.   DIABETES

Transcriptomes of the major human pancreatic cell types

(2011) C. Dorrell et al.   DIABETOLOGIA

Efficient gene delivery and silencing of mouse and human pancreatic islets

(2010) Bruno Lefebvre et al.   BMC BIOTECHNOLOGY

Upgrading Pretransplant Human Islet Culture Technology Requires Human Serum Combined With Media Renewal

(2010) Julie Kerr-Conte et al.   TRANSPLANTATION

CXCL10 Impairs β Cell Function and Viability in Diabetes through TLR4 Signaling

(2009) Fabienne T. Schulthess et al.   Cell Metabolism

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

(2009) M. Obermeier et al.   DRUG METABOLISM AND DISPOSITION

Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus

(2009) Sunil Nair et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes

(2008) S. A. Jabbour et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models

(2008) Y. Fujimori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS